Industry & Policy News

[Sasktoday] University of Saskatchewan (USask) graduate student Ethan Jansen is on a mission to help those affected by emerging global viruses and has joined a team of Canadian researchers leading the charge to discover more about the long-term effects of COVID-19.

[EurekAlert] A Ludwig Cancer Research study has generated a granular portrait of how the cellular and molecular components of the blood vessels that feed brain metastases of melanoma and lung and breast cancers differ from those of healthy brain tissue, illuminating how they help shape the internal environment of tumors to support cancer growth and immune evasion.

[Takeda] Takeda announced that the FDA approved HYQVIA® for the treatment of chronic inflammatory demyelinating polyneuropathy CIDP as maintenance therapy to prevent the relapse of neuromuscular disability and impairment in adults.

[PharmTech.com] Calypso Biotech, a European immunotherapy biotech company focused on the research and development of novel biologics, announced it had agreed to be acquired by Novartis. Calypso’s shareholders are set to receive an upfront payment of $250 million and are eligible to receive development milestones of up to $175 million.

[Science Insider] Four largely ignored coronaviruses circulate in humans without causing great harm and may portend the future for SARS-CoV-2.

[Nature News] Poor-quality studies are polluting the literature — a group will study the businesses that produce them to stem the flow of bogus research.